Abstract
Cancer cells enter the circulation and attach to endothelial cells to pass through them and migrate over a distance to enter the tissue of the metastatic organ to proliferate there. In the same way, neutrophils drift in blood and adhere loosely to adhesive molecules on the endothelial cells in an inflamed area. They roll along the endothelial cells and then adhere closely to the endothelial cells to penetrate vessel wall. Neutrophils can destroy the basement membrane and migrate over a distance to fight against foreign bodies. Thus, the process that both of them follow is quite the same. Neutrophil elastase (NE) is a neutral serine protease which has broad substrate specificity under the physiological conditions, and its excessive production results in digestion of not only elastin, but also other extracellular matrix proteins. This minireview summarizes our recent experimental and clinical studies on NE/NE inhibition and cancer/cancer treatment based on our original view point.
Keywords: Neutrophil Elastase, Cancer Therapy, endothelial cells, metastatic organ, neutral serine protease, plasminogen activator (PA)
Current Enzyme Inhibition
Title: Neutrophil Elastase Inhibition: A New Cancer Therapy
Volume: 4 Issue: 2
Author(s): Takashi Sato, Miwa Yoshida, Satoshi Takahashi, Takashi Fukutomi and Jun-Ichi Yamashita
Affiliation:
Keywords: Neutrophil Elastase, Cancer Therapy, endothelial cells, metastatic organ, neutral serine protease, plasminogen activator (PA)
Abstract: Cancer cells enter the circulation and attach to endothelial cells to pass through them and migrate over a distance to enter the tissue of the metastatic organ to proliferate there. In the same way, neutrophils drift in blood and adhere loosely to adhesive molecules on the endothelial cells in an inflamed area. They roll along the endothelial cells and then adhere closely to the endothelial cells to penetrate vessel wall. Neutrophils can destroy the basement membrane and migrate over a distance to fight against foreign bodies. Thus, the process that both of them follow is quite the same. Neutrophil elastase (NE) is a neutral serine protease which has broad substrate specificity under the physiological conditions, and its excessive production results in digestion of not only elastin, but also other extracellular matrix proteins. This minireview summarizes our recent experimental and clinical studies on NE/NE inhibition and cancer/cancer treatment based on our original view point.
Export Options
About this article
Cite this article as:
Sato Takashi, Yoshida Miwa, Takahashi Satoshi, Fukutomi Takashi and Yamashita Jun-Ichi, Neutrophil Elastase Inhibition: A New Cancer Therapy, Current Enzyme Inhibition 2008; 4 (2) . https://dx.doi.org/10.2174/157340808785107556
DOI https://dx.doi.org/10.2174/157340808785107556 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) Adipose Stem Cells and Skin Repair
Current Stem Cell Research & Therapy Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease
Medicinal Chemistry Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets Design of Novel Antitumor DNA Alkylating Agents: The Benzacronycine Series
Current Medicinal Chemistry - Anti-Cancer Agents Predicating Candidate Cancer-Associated Genes in the Human Signaling Network Using Centrality
Current Bioinformatics Dietary Polyphenols and Mitochondrial Function: Role in Health and Disease
Current Medicinal Chemistry The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Imaging Intraductal Carcinoma
Current Cancer Therapy Reviews Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Novel Methods and Tools of the Computational Systems Biology in Bioinformatics and Biomedical Informatics)
Current Bioinformatics Bone Marker in Women with Breast Cancer
Current Biomarkers (Discontinued) Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued) Repositioning of Difluorinated Propanediones as Inhibitors of Histone Methyltransferases and their Biological Evaluation in Human Leukemic Cell Lines
Anti-Cancer Agents in Medicinal Chemistry SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology